Allergan Receives Complete Response Letter for BOTOX® (Botulinum Toxin Type A) for Treatment of Upper Limb Spasticity...

IRVINE, Calif.--(BUSINESS CORD)-- Allergan, Inc. (NYSE: AGN) today announced it has actually received a comprehensive feedback letter from the UNITED


  1. IRVINE, Calif.--(BUSINESS CORD)-- Allergan, Inc. (NYSE: AGN) today announced it has actually received a comprehensive feedback letter from the UNITED STATE Meals and Drug Management (FDA) pertaining to the Company's Supplemental Biologics Permit Application (sBLA) for BOTOX (Botulinum Toxin Kind A) to manage top arm or leg spasticity in post-stroke grownups. Allergan submitted its sBLA for this sign in the third quarter of 2008.

    The FDA has actually not requested additional pre-approval clinical researches. However, the FDA has recognized items that should be finished before the sBLA can be considered for authorization, including the following:

    1. Risk Assessment and Minimization Strategy (REMS) and Security Update:

    On April 29, 2009, the FDA approved DYSPORT(TM) (abobotulinumtoxinA) for the treatment of cervical dystonia in adults and the temporary improvement in the appearance of mild to severe glabellar lines in grownups more youthful than 65 years of age and imposed a REMS for that product. Simultaneously, the FDA requested that Allergan embrace a significantly similar REMS for BOTOX. Allergan has actually submitted its proposed REMS for the FDA's review. The FDA indicated that it had actually not yet reviewed Allergan's entry and that an accepted REMS will certainly be needed before accepting BOTOX to manage top arm or leg spasticity. Additionally, the FDA asked for that in its reply to the full feedback letter, Allergan provide an item security upgrade from scientific and non-clinical researches throughout indications.

    2. Source Information Paperwork:

    While the FDA's total response letter recognizes that the sBLA sustains the efficacy and safety and security of BOTOX for the treatment of upper arm or leg spasticity, the FDA has actually requested that Allergan separately validate hiddening patient source paperwork at research study websites connecting to one of the essential professional studies conducted in 1999 and upon conclusion of the verification, provide an updated evaluation. In the sBLA, Allergan sent data from 16 studies consisting of an integrated analysis of 7 double-blind, placebo-controlled trials.

    Allergan estimates that the re-verification could be filled out and the analysis accepted the FDA in about 60 to 90 days.

    3. Item Labeling:

    In its total feedback letter, the FDA proposed alterations to Allergan's recommended classifying, consisting of enhanced safety information and various other clarifications. Among various other modifications, the FDA suggested a revised spasticity sign. In its sBLA, Allergan suggested the usage of BOTOX for the procedure of upper limb spasticity linked with movement. In its full reaction letter, the FDA kept in mind the focal attributes of BOTOX therapies and the similarities of spasticity throughout problems and hence recommended modified labeling that would certainly expand the indicator of usage to upper arm or leg spasticity no matter hiddening source. Also, keeping in mind the variety of pediatric individuals such as those with adolescent cerebral palsy which endure from upper arm or leg spasticity, the FDA asked for that Allergan conduct a post-approval study for BOTOX to treat upper limb spasticity in pediatric patients 2-17 years old. This demand follows Allergan's proposal about the submission of its suggested REMS and Allergan intends to talk about with the FDA a protocol that, if successful, would certainly sustain an approval for the therapy of kids experiencing from spasticity.

    Allergan will hard react to the FDA's proposed tag alterations and will create a pediatric strategy to more research study BOTOX in youngsters.

    "A substantial unmet medical necessity for those experiencing from top arm or leg spasticity alreadies existing in the Usa. It is determined that almost 500,000 Americans every year establish stroke-related spasticity, most which consists of upper limb spasticity1,2. And yet concerning fifty percent of those people get no procedure for their spasticity," said Scott Whitcup, M.D., Executive Vice Head of state, Study & & Advancement, Chief Scientific Policeman, Allergan, Inc. "We have actually already submitted our REMS for BOTOX as we expected this need as a disorder to an accepted spasticity sign. We will certainly work expeditiously to offer the FDA with all other details requested in the complete feedback letter to sustain a quick final evaluation of our application for BOTOX as a treatment for upper arm or leg spasticity."

    About BOTOX BOTOX is a prescription-only medical product that has small amounts of highly purified botulinum poisonous substance protein refined from the microorganism, Clostridium botulinum. When administered at accepted and identified doses into a certain muscle or gland, BOTOX is anticipated to diffuse locally and anticipated to produce a safe and effective outcome by creating a localized and momentary reduction in the overacting muscular tissue or gland, typically lasting in between 3 and 6.7 months depending on the specific patient and indicator.

    BOTOX was first accepted by the FDA virtually twenty years ago for the treatment of strabismus and blepharospasm, 2 eye muscle problems, making it the first botulinum toxin kind A product authorized around the world. Since its initial authorization, BOTOX has been acknowledged by regulatory authorities worldwide as a reliable treatment for 21 various indicators in approximately 80 nations, benefiting millions of individuals worldwide. In the United States, BOTOX is additionally accepted for the treatment of cervical dystonia in grownups to decrease the intensity of irregular head placement and neck discomfort related to the condition, and for the treatment of extreme primary axillary hyperhidrosis (extreme underarm sweating) that is inadequately taken care of with topical brokers. Along with its therapeutic pre-owneds, the very same formula of BOTOX with dosing specific to botox boston ma glabellar lines was approved by the FDA in 2002 under the field name BOTOX Cosmetic.

    In addition to almost Twenty Years of medical experience, the security and effectiveness of BOTOX have been well-established in roughly 50 randomized, placebo-controlled clinical trials and in approximately 11,000 clients addressed with BOTOX and BOTOX Cosmetic in Allergan's medical trials3.

    Essential BOTOX and BOTOX Cosmetic (Botulinum Poisonous substance Kind A) Information

    BOTOX is shown for the treatment of cervical dystonia in grownups to minimize the severity of unusual head placement and neck pain associated with cervical dystonia.

    BOTOX is likewise shown for the therapy of strabismus and blepharospasm linked with dystonia, including curable necessary blepharospasm or VII nerve conditions in patients 12 years of age and above.

    The efficacy of BOTOX treatment in inconsistencies over FIFTY prism diopters, in restrictive strabismus, in Duane's syndrome with side rectus weakness, and in additional strabismus created by prior surgical over-recession of the antagonist has not been developed. BOTOX is inefficient in persistent paralytic strabismus other than when utilized along with surgical repair work to decrease antagonist contracture.

    And BOTOX is suggested for the treatment of severe key axillary hyperhidrosis that is inadequately managed with topical agents.

    BOTOX Cosmetic is authorized for the short-term procedure of modest to intense frown lines between the brows in folks ages 18-65.

    Vital BOTOX and BOTOX Cosmetic (Botulinum Poisonous substance Type A) Safety and security Details

    BOTOX and BOTOX Aesthetic therapy must not be injected in the visibility of infection at the suggested treatment site(s) and in people with recognized irritation to any type of element in the formula.

    Serious heart troubles and serious allergic reactions have been stated rarely. If you believe you're having a sensitive response or other unusual symptoms, such as difficulty ingesting, talking or breathing, call your medical professional right away. People with peripheral motor neuropathic conditions (e.g., amyotrophic side sclerosis, or electric motor neuropathy) or neuromuscular junctional ailments (e.g., myasthenia gravis or Lambert-Eaton disorder) must just receive BOTOX or BOTOX Cosmetic with caution. Clients with neuromuscular ailments could go to improved danger of technically considerable systemic negative side effects with BOTOX or BOTOX Cosmetic.

    BOTOX for Blepharospasm in Clients )= 12 Years old: Reduced blinking from BOTOX shot of the orbicularis muscle could bring about corneal exposure, persistent epithelial flaw and corneal perforation. The most frequently reported treatment-related damaging reactions in these individuals are ptosis (20.8 %), superficial punctate keratitis (6.3 %) and eye dryness (6.3 %).

    BOTOX for Strabismus in Patients )= 12 Years of Age: Causing paralysis in several extraocular muscles could produce spatial disorientation, double vision or past pointing. One of the most commonly mentioned negative effects are ptosis (16 %) and upright inconsistency (17 %).

    BOTOX for Cervical Dystonia in Grownups: There have actually been uncommon cases of dysphagia extreme sufficient to require the insertion of a stomach eating tube. The most often stated unfavorable responses in clients with cervical dystonia are dysphagia (19 %), top breathing infection (12 %), neck pain (11 %), and headache (11 %).

    BOTOX for Severe Main Axillary Hyperhidrosis Inadequately Managed with Topical Brokers: One of the most regularly mentioned negative events (3 - 10 %) are injection site pain and hemorrhage, non-axillary sweating, infection, pharyngitis, influenza syndrome, headache, fever, neck or pain in the back, pruritus, and stress and anxiety.

    BOTOX Cosmetic for Temporary Renovation in the Appearance of Moderate to Severe Frown Lines In between the Brows in Adults 18-65: The most usual negative side effects adhering to shot include short-lived eyelid droop and nausea. Local discomfort, infection, irritation, tenderness, swelling, redness and/or bleeding/bruising might be related to the shot.

    Extra Important Safety Information

    The FDA on April 30, 2009, in its upgrade to the early communication sent out in 2008, provided the following referrals:

    Comprehend that dosage strength (effectiveness) expressed in "Devices" or "U" are different among the botulinum contaminant products; professional doses revealed in devices are not interchangeable from one botulinum contaminant item to one more.

    Be alert to and educate individuals and caretakers about prospective unpleasant events due to distant spread of botulinum contaminant impacts complying with local injections consisting of: unanticipated loss of toughness or muscle weakness, hoarseness or difficulty talking (dysphonia), problem claiming words clearly (dysarthria), loss of bladder control, problem breathing, problem ingesting, double vision, blurred vision and sagging eyelids.

    Understand that these negative events have actually been reported as early as a number of hours and as late as several weeks after therapy.

    Advise patients to look for prompt med attention if they establish any of these signs.

    For complete suggesting information, kindly browse through and

    Forward-Looking Declaration

    This press release contains "progressive declarations," consisting of the declarations by Dr. Whitcup and various other statements regarding the security, efficiency, negative events, approval and market possible related to BOTOX. These declarations are based upon current assumptions of future occasions. If hiddening presumptions verify unreliable or not known risks or uncertainties emerge, real outcomes could possibly differ materially from Allergan's assumptions and forecasts. Dangers and uncertainties consist of, amongst various other points, general market, biologic and pharmaceutical market disorders; technical advances and licenses achieved by competitors; difficulties fundamental in the study and development and governing processes; inconsistency of treatment outcomes amongst patients; prospective problems in production; general economic disorders; and governmental legislations and laws influencing domestic and overseas operations. Extra information concerning these and other risk aspects could be discovered in press releases provided by Allergan, along with Allergan's public periodic filings with the Stocks and Exchange Payment, consisting of the conversation under the heading "Danger Factors" in Allergan's 2008 Form 10-K and Allergan's Kind 10-Q for the quarter ended March 31, 2009. Copies of Allergan's press launches and additional info regarding Allergan is offered on the Net at or you can get in touch with the Allergan Investor Relations Division by calling 1-714-246-4636.

    Regarding Allergan, Inc.

    . Founded in 1950, Allergan, Inc., with base of operations in Irvine, California, is a multi-specialty healthcare business that uncovers, develops and commercializes ingenious drugs, biologics and medical devices that make it possible for folks to live life to its greatest possibility - to view even more clearly, move a lot more easily, express themselves more totally. The Business employs roughly 8,000 folks around the world and runs state-of-the-art R&D centers and world-class production plants. In addition to its discovery-to-development research organization, Allergan has worldwide advertising and marketing and sales abilities with an existence in greater than 100 countries.

    2009 Allergan, Inc. Irvine, CA 92612. marks owned by Allergan, Inc.

    1 Watkins CL, Leathley MJ, Gregson JM, Moore AP, Smith TL, Sharma AK. Occurrance of spasticity post movement. Clin Rehabil. 2002; 16(5):515 -22

    2 National Stroke Association. New survey stresses demand for much more, better treatment after movement. National Stroke Organization Website. . Accessed February 20, 2009.

    3 Allergan information on data; Medical Affairs